Which strategies reduce breast cancer mortality most?: Collaborative modeling of optimal screening, treatment, and obesity prevention

Cancer

Volumn 119, Issue 14, 2013, Pages 2541-2548

  Mandelblatt, Jeanne ^a   Van Ravesteyn, Nicolien ^b   Schechter, Clyde ^c   Chang, Yaojen ^a   Huang, An Tsun ^a   Near, Aimee M ^a   De Koning, Harry ^b   Jemal, Ahmedin ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d AMERICAN CANCER SOCIETY   (United States)

Author keywords

breast cancer; mammography; modeling; obesity; simulation; treatment

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CAUSE OF DEATH; DIGITAL MAMMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT PLANNING;

BREAST CANCER; MAMMOGRAPHY; MODELING; OBESITY; SIMULATION; TREATMENT;

ADULT; AGED; BREAST NEOPLASMS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; OBESITY; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84879613833     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28087     Document Type: Article

References (54)

1. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med. 2005; 353: 1784-1792.
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
3. Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996; 14: 3000-3008.
4. Gorin SS, Heck JE, Cheng B, Smith SJ,. Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med. 2006; 166: 2244-2252.
5. Griggs JJ, Sorbero ME, Lyman GH,. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005; 165: 1267-1273.
6. Colleoni M, Li S, Gelber RD, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet. 2005; 366: 1108-1110.
7. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000; 152: 514-527.
8. Carmichael AR, Bates T,. Obesity and breast cancer: a review of the literature. Breast. 2004; 13: 85-892.
9. Vona-Davis L, Rose DP,. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009; 18: 883-893.
10. Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ,. A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr. 2006; 36: 96-105.
11. Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD,. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr. 2006; 36: 56-65.
12. Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J,. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000. J Natl Cancer Inst Monogr. 2006; 36: 47-55.
13. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009; 151: 738-747.
14. van Ravesteyn NT, Schechter CB, Near AM, et al. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Epidemiol Biomarkers Prev. 2011; 20: 112-122.
15. Chang Y, Schechter CB, van Ravesteyn NT, et al. Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality. Breast Cancer Res Treat. 2012; 136: 823-835.
16. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2012. Atlanta: American Cancer Society, Inc. http://www.cancer. org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-033423. pdf. Accessed October 2012.
17. CISNET Cancer Intervention and Surveillance Modeling Network. http://cisnet.cancer.gov. Accessed May 2012.
18. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology v.2. 2008. http://www.nccn.org/professional/physician-gls/f- guidelines.asp. Accessed September 2009.
19. Carter SB, Gartner SS, Haines MR, et al. Historical Statistics of the United States, Volume One: Population. New York: Cambridge University Press, 2006.
20. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, CDC. http://www/cdc/gov/nchs/nhanes.htm. Accessed May 2012.
21. Wang YC, Graubard BI, Rosenberg MA, et al. Derivation of background mortality by smoking and obesity in cancer stimulation models. Med Decis Making. 2013; 33: 176-197.
22. Wang YC, Colditz GA, Kuntz KM,. Forecasting the obesity epidemic in the aging U.S. population. Obesity. 2007; 15: 2855-2865.
23. Wang Y, Beydoun MA,. The obesity epidemic in the United States - gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007; 29: 6-28.
24. Flegal K, Carroll M, Ogden C, Johnson C,. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012; 307: 491-497.
25. Holford TR, Cronin KA, Mariotto AB, Feuer EJ,. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006; 19-25.
26. Cronin KA, Mariotto AB, Clarke LD, Feuer EJ,. Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality. J Natl Cancer Inst Monogr. 2006; 26-29.
27. Cronin KA, Yu B, Krapcho M, et al. Modeling the dissemination of mammography in the United States. Cancer Causes Control. 2005; 16: 701-712.
28. Zhu K, Wu H, Jatoi I, Potter J, Shriver C,. Body mass index and use of mammography screening in the United States. Prev Med. 2006; 381-385.
29. Breast Cancer Surveillance Consortium. Performance Measures for 3,884,059 Screening Mammography Examinations from 1996 to 2007 by Age-based on BCSC data as of 2008. http://breastscreening.cancer.gov/data/performance/screening/2008/ perf-age.html. Accessed April 2008.
30. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W,. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975-2007/. Accessed January 2012.
31. Cui Y, Whiteman M, Flaws J, et al. Body mass and stage of breast cancer at diagnosis. Int J Cancer. 2002; 98: 279-283.
32. Hahn KM, Bondy ML, Selvan M, et al. Factors associated with advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed breast cancer. Am J Epidemiol. 2007; 166: 1035-1044.
33. Bekele BN, Nieto-Barajas LE, Munsell MF,. Analysis of partially incomplete tables of breast cancer patients' characteristics with an ordinal variable. J Stat Theory Pract. 2012 [in press].
34. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A,. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer. 2009; 124: 698-712.
35. Mariotto AB, Feuer EJ, Harlan LC, Abrams J,. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr. 2006; 7-15.
36. Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J,. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 2002; 94: 1626-1634.
37. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
38. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998; 352: 930-942.
39. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351: 1451-1467.
40. Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008; 371: 29-40.
41. National Center for Health Statistics. United States, 2000. Hyattsville, Maryland: Public Health Service 2000. http://www.cdc.gov/nchs/products/life- tables.htm. Accessed May 2012.
42. Human Mortality Database, Centers for Disease Control and Prevention, Publications and Information Products, Life Tables 2011. http://www.mortality. org. Accessed May 2012.
43. Rosenberg MA,. Competing risks to breast cancer mortality. J Natl Cancer Inst Monogr. 2006; 15-19.
44. Projected population by single year of age, sex, race, and hispanic origin for the United States: July 1, 2000 to July 1, 2050. http://www.census. gov/population/www/projections/downloadableflies.html. Accessed May 2012.
45. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011; 126: 529-537.
46. Wigertz A, Ahlgren J, Holmqvist M, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012; 133: 367-73.
47. Trivedi AN, Rakowski W, Ayanian JZ,. Effect of cost sharing on screening mammography in Medicare health plans. New Engl J Med. 2008; 358: 375-383.
48. Vernon SW, McQueen A, Tiro JA, del Junco DJ,. Interventions to promote repeat breast cancer screening with mammography: a systematic review and meta-analysis. J Natl Cancer Inst. 2010; 102: 1023-1039.
49. Bleyer A, Welch HG,. Effect of three decades of screening mammogrpahy on breast cancer incidence. New Engl J Med. 2012; 367: 1998-2005.
50. de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ,. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev. 2011; 33: 111-121.
51. Mandelblatt JS, Stout N, Trentham-Dietz A,. To screen or not to screen women in their 40s for breast cancer: is personalized risk-based screening the answer? Ann Internal Med. 2011; 155: 58-60.
52. Elmore JG, Reisch LM, Barton MB, et al. Efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst. 2005; 97: 1035-1043.
53. Goodwin P,. Energy balance and cancer prognosis. In: McTiernan A. Mechanisms Associating Physical Activity With Cancer Incidence: Exercise and Immune Function. Boca Raton, FL: Taylor & Francis Group, LLC; 2006: 405-436.
54. Bonomi AE, Boudreau DM, Fishman PA, et al. Quality of life valuations of mammography screening. Qual Life Res. 2008; 17: 801-814.